Sign in
Taking people in ItalyPhase 2

Maribavir for cytomegalovirus infection after stem cell transplant when usual antivirals cannot be used

Tests maribavir against cytomegalovirus infection in stem cell transplant recipients who cannot take usual antivirals.

Key facts

Who runs it
Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare
Where
Alexandria, Bergamo, Bologna, Brescia, Cagliari, Florence, Genoa, Milan, Monza, Naples, Palermo, Perugia, Reggio Calabria, Rome, San Giovanni Rotondo, Turin, and Udine, ItalySee the 20 sites
Registry title
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
Status
Recruiting
Phase
Phase 2
People taking part
81 people, planned
Started
15 May 2026
Expected to end
30 Sept 2028
Type of study
Interventional
Record updated
17 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with CMV infection who had a donor stem cell transplant in the past twelve months. They either cannot take ganciclovir, valganciclovir or foscarnet for medical reasons, or stopped these drugs due to side effects.

Age
Over 18 years.
Sex
All sexes can join.
Disease stage
CMV infection after a donor (allogeneic) stem cell transplant done within the previous twelve months. Daily activity level ECOG <3. No diarrhea or active bowel disease. Weight ≥40 kg (88 lb). Able to swallow tablets.
Earlier treatment
Either a medical condition that rules out ganciclovir, valganciclovir or foscarnet (such as kidney problems, slow bone marrow recovery, or past side effects from these drugs), or first-line treatment with these drugs was stopped due to side effects or intolerance.
Biomarker or test result
Bilirubin ≤2 UNL; ALT/AST ≤2,5 UNL; creatinine clearance ≥50 ml/min.

Main reasons for not taking part

  • CMV disease that has spread to organs
  • Severe vomiting, diarrhea or bowel illness within 24 hours before the first dose that prevents taking pills
  • Any active, uncontrolled infection or other life-threatening illness
  • Known allergy to any part of the study medicine
  • Being in another clinical trial within 1 month before this trial

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Allogeneic hematopoietic stem cell transplant performed within previous twelve months
  • Absence of diarrhea or other intestinal symptoms or active intestinal pathology
  • Life expectancy not severely limited by concomitant illness
  • Women of childbearing potential must use highly effective contraception for at least 1 month after the last dose of maribavir
  • Willing and able to comply with all of the requirements and visits in the protocol
  • ten and signed informed consent
  • Diagnosis of CMV infection
  • Patients with a medical condition that contraindicate the administration of ganciclovir, valganciclovir of foscarnet (patients with kidney failure, kidney disease, kidney dysfunction; patients with delayed state or degree of bone marrow engraftment; patients with previous CMV infections who have experienced SoC toxicity), or patients who discontinued first line antiviral therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance
  • Age > 18 years
  • Weigh ≥40 kg
  • Able to swallow tablets
  • Performance status: ECOG <3
  • Adequate hepatic function (bilirubin ≤2 UNL; ALT/AST ≤2,5 UNL)
  • Adequate renal function (creatinine clearance ≥50 ml/min)

Who cannot take part

  • Severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the first dose of study drug that would preclude administration of oral/enteral medication
  • Patients with other life-threatening concurrent disease
  • Participation in another clinical trial within 1 month before the start of this trial
  • Any active, uncontrolled infection
  • End-organ CMV disease
  • Subjects with known hypersensitivity to any of the component medication
  • Non-cooperative behaviour or non-compliance

Where in Italy

  • Azienda Ospedaliero-Universitaria Ss.Antonio E Biagio E C.Arrigo AlessandriaAlexandria, ItalyTaking people
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIIIBergamo, ItalyTaking people
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBrescia, ItalyTaking people
  • ARNAS G. BrotzuCagliari, ItalyTaking people
  • Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyTaking people
  • IRCCS Ospedale Policlinico San MartinoGenoa, ItalyTaking people
  • ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
  • Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
  • Fondazione IRCCS San Gerardo dei TintoriMonza, ItalyTaking people
  • Azienda Ospedaliera di Rilievo Nazionale Antonio CardarelliNaples, ItalyTaking people
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia - CervelloPalermo, ItalyTaking people
  • Azienda Ospedaliera di PerugiaPerugia, ItalyTaking people
  • Grande Ospedale Metropolitano Bianchi Melacrino MorelliReggio Calabria, ItalyTaking people
  • Azienda Ospedaliera Policlinico Universitario Tor VergataRome, ItalyTaking people
  • Azienda Ospedaliero-Universitaria Policlinico Umberto IRome, ItalyTaking people
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
  • Casa Sollievo della SofferenzaSan Giovanni Rotondo, ItalyTaking people
  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di TorinoTurin, ItalyTaking people
  • Azienda Sanitaria Universitaria Friuli CentraleUdine, ItalyTaking people

About the trial

What the trial wants to find out

- To evaluate the efficacy of maribavir, at the end of Study Week 8, in HSCT recipients with CMV infection treated with the antiviral drug as first line therapy in patients with 1) a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and 2) as second line therapy in patients who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.

Read full original descriptionShow less

- To assess the side effects requiring treatment discontinuation of maribavir in HSCT recipients with CMV infection administered as first line therapy in patients with 1) a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and 2) as second line therapy in those who discontinued first line preemptive antiviral therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
Plain-language title
Maribavir for cytomegalovirus infection after stem cell transplant when usual antivirals cannot be usedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
17 November 2025